ATRC vs. ATEC, OFIX, SRDX, INO, IART, NVCR, MDXG, LMAT, AORT, and FNA
Should you be buying AtriCure stock or one of its competitors? The main competitors of AtriCure include Alphatec (ATEC), Orthofix Medical (OFIX), Surmodics (SRDX), Inovio Pharmaceuticals (INO), Integra LifeSciences (IART), NovoCure (NVCR), MiMedx Group (MDXG), LeMaitre Vascular (LMAT), Artivion (AORT), and Paragon 28 (FNA). These companies are all part of the "medical" sector.
AtriCure (NASDAQ:ATRC) and Alphatec (NASDAQ:ATEC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, community ranking, profitability, risk, valuation, institutional ownership and dividends.
In the previous week, AtriCure had 24 more articles in the media than Alphatec. MarketBeat recorded 30 mentions for AtriCure and 6 mentions for Alphatec. Alphatec's average media sentiment score of 0.61 beat AtriCure's score of 0.00 indicating that Alphatec is being referred to more favorably in the news media.
AtriCure has a net margin of -8.98% compared to Alphatec's net margin of -38.70%. Alphatec's return on equity of 0.00% beat AtriCure's return on equity.
AtriCure currently has a consensus target price of $49.78, indicating a potential upside of 138.29%. Alphatec has a consensus target price of $23.63, indicating a potential upside of 73.08%. Given AtriCure's higher possible upside, equities analysts plainly believe AtriCure is more favorable than Alphatec.
AtriCure received 235 more outperform votes than Alphatec when rated by MarketBeat users. Likewise, 68.98% of users gave AtriCure an outperform vote while only 56.52% of users gave Alphatec an outperform vote.
AtriCure has higher earnings, but lower revenue than Alphatec. AtriCure is trading at a lower price-to-earnings ratio than Alphatec, indicating that it is currently the more affordable of the two stocks.
AtriCure has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500.
99.1% of AtriCure shares are owned by institutional investors. Comparatively, 66.4% of Alphatec shares are owned by institutional investors. 3.2% of AtriCure shares are owned by company insiders. Comparatively, 29.1% of Alphatec shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
AtriCure beats Alphatec on 9 of the 16 factors compared between the two stocks.
Get AtriCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AtriCure Competitors List
Related Companies and Tools
